TY - JOUR
T1 - Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma
AU - Bollard, Catherine M.
AU - Tripic, Tamara
AU - Cruz, Conrad Russell
AU - Dotti, Gianpietro
AU - Gottschalk, Stephen
AU - Torrano, V.
AU - Dakhova, Olga
AU - Carrum, G.
AU - Ramos, C. A.
AU - Liu, H.
AU - Wu, Meng Fen
AU - Marcogliese, Andrea N.
AU - Barese, Cecilia
AU - Zu, Youli
AU - Lee, Daniel Y.
AU - O’Connor, O.
AU - Gee, Adrian P.
AU - Brenner, Malcolm
AU - Heslop, Helen
AU - Rooney, Cliona M.
N1 - Funding Information:
Supported by National Institutes of Health Grant No. P01-CA094237, SPORE in Lymphoma Grant No. P50-CA126752, and a Leukemia and Lymphoma Society SCOR Grant No. 7018-04, as well as by the shared resources of the Dan L. Duncan Cancer Center support Grant No. P30-CA125123
Publisher Copyright:
© 2018 by American Society of Clinical Oncology. All rights reserved.
PY - 2018/4/10
Y1 - 2018/4/10
N2 - Purpose Transforming growth factor-b (TGF-b) production in the tumor microenvironment is a potent and ubiquitous tumor immune evasion mechanism that inhibits the expansion and function of tumor-directed responses; therefore, we conducted a clinical study to discover the effects of the forced expression of a dominant-negative TGF-b receptor type 2 (DNRII) on the safety, survival, and activity of infused tumor-directed T cells. Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus–positive Hodgkin lymphoma received two to 12 doses of between 2 3 10 7 and 1.5 3 10 8 cells/m 2 of DNRII-expressing T cells with specificity for the Epstein Barr virus–derived tumor antigens, latent membrane protein (LMP)-1 and LMP-2 (DNRII-LSTs). Lymphodepleting chemotherapy was not used before infusion. Results DNRII-LSTs were resistant to otherwise inhibitory concentrations of TGF-b in vitro and retained their tumor antigen–specific activity. After infusion, the signal from transgenic T cells in peripheral blood increased up to 100-fold as measured by quantitative polymerase chain reaction for the transgene, with a corresponding increase in the frequency of functional LMP-specific T cells. Expansion was not associated with any acute or long-term toxicity. DNRII-LSTs persisted for up to $ 4 years. Four of the seven evaluable patients with active disease achieved clinical responses that were complete and ongoing in two patients at . 4 years, including in one patient who achieved only a partial response to unmodified tumor-directed T cells. Conclusion TGF-b–resistant tumor-specific T cells safely expand and persist in patients with Hodgkin lymphoma without lymphodepleting chemotherapy before infusion. DNRII-LSTs can induce complete responses even in patients with resistant disease. Expression of DNRII may be useful for the many other tumors that exploit this potent immune evasion mechanism.
AB - Purpose Transforming growth factor-b (TGF-b) production in the tumor microenvironment is a potent and ubiquitous tumor immune evasion mechanism that inhibits the expansion and function of tumor-directed responses; therefore, we conducted a clinical study to discover the effects of the forced expression of a dominant-negative TGF-b receptor type 2 (DNRII) on the safety, survival, and activity of infused tumor-directed T cells. Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus–positive Hodgkin lymphoma received two to 12 doses of between 2 3 10 7 and 1.5 3 10 8 cells/m 2 of DNRII-expressing T cells with specificity for the Epstein Barr virus–derived tumor antigens, latent membrane protein (LMP)-1 and LMP-2 (DNRII-LSTs). Lymphodepleting chemotherapy was not used before infusion. Results DNRII-LSTs were resistant to otherwise inhibitory concentrations of TGF-b in vitro and retained their tumor antigen–specific activity. After infusion, the signal from transgenic T cells in peripheral blood increased up to 100-fold as measured by quantitative polymerase chain reaction for the transgene, with a corresponding increase in the frequency of functional LMP-specific T cells. Expansion was not associated with any acute or long-term toxicity. DNRII-LSTs persisted for up to $ 4 years. Four of the seven evaluable patients with active disease achieved clinical responses that were complete and ongoing in two patients at . 4 years, including in one patient who achieved only a partial response to unmodified tumor-directed T cells. Conclusion TGF-b–resistant tumor-specific T cells safely expand and persist in patients with Hodgkin lymphoma without lymphodepleting chemotherapy before infusion. DNRII-LSTs can induce complete responses even in patients with resistant disease. Expression of DNRII may be useful for the many other tumors that exploit this potent immune evasion mechanism.
UR - http://www.scopus.com/inward/record.url?scp=85044231117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044231117&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.74.3179
DO - 10.1200/JCO.2017.74.3179
M3 - Article
C2 - 29315015
AN - SCOPUS:85044231117
VL - 36
SP - 1128
EP - 1139
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 11
ER -